linjc16/ctgov huggingface dataset:
Phenotyping and Genotyping of Duffy Antigen

Study Overview
=================
Brief Summary
-----------------
Malaria remains the world's leading parasitic endemic. Almost half of the world's population lives in endemic areas. Many at-risk people in African countries remain without access to malaria control. Malaria kills approximately 400,000 people each year, most of whom are children under the age of 5 in Africa. Since 2005, an increasing number of Plasmodium vivax infections have been observed in Duffy-negative populations in South America and Africa, calling into question the essential role of the PvDBP-DARC interaction. The objective of the investigators is therefore to study and understand the invasion pathways used by Plasmodium vivax in Duffy-negative subjects.

Official Title
-----------------
Phenotyping and Genotyping of Duffy Antigen

Conditions
-----------------
Plasmodium Vivax

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Major subjects with malaria and willing to have their blood samples analyzed for this research Exclusion Criteria: Subjects refusing to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of blood samples tested (phenotype and genotype). |  | 2 months later | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Malaria, Malaria, Vivax, PvDBP-DARC interaction, Plasmodium vivax, Duffy-negative, Duffy Binding Protein, PvDBP, Duffy Antigen Receptor for Chemokines
A Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients

Study Overview
=================
Brief Summary
-----------------
Examine the ability of Timunox (thymopentin) to reduce the amount and/or frequency of virus isolation. Examine the ability of thymopentin to stimulate the immune system and alter the clinical findings in patients infected with HIV who do not yet have AIDS.

Official Title
-----------------
A Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: Thymopentin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Concurrent Medication: Allowed: Aerosolized pentamidine. Patients must have the following: Seropositive for HIV-1 (ELISA assay) confirmed by Western blot. HIV-1 p24 antigen must be detected in supernatant fluids from co-cultures of patients' PBMC on two separate occasions. Voluntarily sign consent. Patients with HIV wasting syndrome are allowed. Prior Medication: Allowed: Aerosolized pentamidine. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: AIDS as defined by the CDC. Significant hepatic disease. Thrombocytopenia. Hypersensitivity to thymopentin. Hemophilia A or B or other hematologic disorders requiring current or previous administration of blood products. Abnormal chest x-ray (indicative of active disease (opportunistic infection)) within 30 days prior to study entry. Patients with the following are excluded: AIDS as defined by the CDC. Significant hepatic disease. Thrombocytopenia. Hypersensitivity to thymopentin. Hemophilia A or B or other hematologic disorders requiring current or previous administration of blood products. Abnormal chest x-ray (indicative of active disease (opportunistic infection)) within 30 days prior to study entry. Prior Medication: Excluded within 30 days of study entry: Immunomodulatory or experimental therapy. Excluded within 90 days of study entry: Zidovudine (AZT). Intravenous drug abuse.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Thymopentin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Semen, Thymopentin, Leukocytes, Mononuclear, AIDS-Related Complex
Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to test the effectiveness of a marketed drug in the treatment of a menstrual migraine attack.

Official Title
-----------------
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg Tablets for the Treatment of Menstrual Migraine

Conditions
-----------------
Migraine

Intervention / Treatment
-----------------
* Drug: MK0462, rizatriptan benzoate / Duration of Treatment -1day
* Drug: Comparator: placebo / Duration of Treatment - 1 day


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female patient at least 18 years old Patient has menses approximately monthly Patient has at least a 6 month history of migraine and at least a 6 month history of menstrual migraine Exclusion Criteria: Pregnant and/or nursing mother Cardiovascular disease Uncontrolled hypertension

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: MK0462, rizatriptan benzoate / Duration of Treatment -1day|nan|
|Drug: Comparator: placebo / Duration of Treatment - 1 day|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients with 2 hour pain relief: 4-point headache severity scale as recorded in patient diary |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients with 24-hr sustained pain relief: headache severity between 2 and 24 hrs post dose recorded in patient diary |  |  |
Combined Intravitreal Fasudil and Bevacizumab for Diabetic Macular Edema

Study Overview
=================
Brief Summary
-----------------
Eligible eyes are randomized to two groups. Group A will receive three intravitreal injections of bevacizumab at 4 week intervals. In group B, three intravitreal injections of combined bevacizumab and fasudil will be performed with the same frequency. Best corrected visual acuity (BCVA) and central macular thickness (CMT) will be evaluated prior to injections and then every 4 weeks for 6 months. Fluorescein angiography will be performed at baseline and at weeks 12 and 24. The two groups will be compared in terms of BCVA and CMT changes.

Conditions
-----------------
Diabetic Macular Edema

Intervention / Treatment
-----------------
* Drug: Intravitreal injection of bevacizumab (Avastin)
* Drug: Intravitreal injection of fasudil and bevacizumab (Avastin)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diabetic patients with diabetic macular edema (DME) and: Central macula thickness> 250μm Visual acuity < 20/40 No active proliferative diabetic retinopathy No history of intravitreal anti-VEGF drug injection or macular laser photocoagulation (MPC) within the past 3 months Exclusion Criteria: History of vitrectomy History of cataract surgery within the past 6 months History of glaucoma or uveitis Presence of any macular disorder other than DME Presence of traction on the macula Significant media opacity Serum creatinine>3mg/ml
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Intravitreal bevacizumab (Avastin)<br>Dosage: 1.25 mg/0.05 ml Frequency: 3 consecutive injections every 4 weeks | Drug: Intravitreal injection of bevacizumab (Avastin)<br> <br> |
| Active Comparator: Combined intravitreal fasudil and bevacizumab (Avastin)<br>Dosage: bevacizumab 1.25 mg/0.05 ml + fasudil 0.025mg/0.05ml Frequency: 3 consecutive injections every 4 weeks | Drug: Intravitreal injection of fasudil and bevacizumab (Avastin)<br>* intravitreal injections of bevacizumab and fasudil are performed at two different sites (superior temporal and inferior temporal quadrants respectively)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Best corrected visual acuity | Snellen E-chart | 6 months | 
| central macular thickness | spectral domain optical coherence tomography (SD OCT) | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Status of macular perfusion | Heidelberg fluorescein angiogram (HRA II) | 6 months | 
| intraocular inflammation | clinical examination | 6 months |
Electrochemical Skin Conductance in Evaluation of Chronic Neuropathy électrochimique cutanée

Study Overview
=================
Brief Summary
-----------------
Use of cutaneous electrochemical conductance for preclinical screening of small-caliber nerve fibers

Detailed Description
-----------------
Objective: Use of cutaneous electrochemical conductance for preclinical screening of small-caliber nerve fibers Background: Sudoscan is a tool developed to evaluate and screen peripheral neuropathies in diabetes. His indication has been extended to other neuropathies such as post-chemotherapy, Fabry's disease, Parkinson's disease, familial amyloid polyneuropathy. Main objective: Evaluation of the relevance of cutaneous electrochemical conductance in chronic peripheral neuropathies. Methodology : Recruitment of 2 groups of 2000 patients Group 1: Patients with chronic neuropathy, during clinic bread consultation Group 2: Patients to benefit from scheduled surgery seen during anesthesia consultation For both groups filling the central awareness inventory questionnaire Analysis of the results after the recruitment has been completed.

Official Title
-----------------
Electrochemical Skin Conductance in Evaluation of Chronic Neuropathy

Conditions
-----------------
Difference, Individual

Intervention / Treatment
-----------------
* Device: SUDO-SCAN Device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult Exclusion Criteria: Patients group : Not have a chronic neuropathy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Parallel group open label Monocentric
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Test<br>2000 patients healthy in anesthesiology consultation | Device: SUDO-SCAN Device<br>* Sudo-scan is a machine with 2 palets for hands and 2 palets for foots. The patient has to put his 2 hands and 2 foots on the machine. The machine do the measures during 2 minutes.<br>|
| Experimental: Patients<br>2000 patients in pain clinic consultation | Device: SUDO-SCAN Device<br>* Sudo-scan is a machine with 2 palets for hands and 2 palets for foots. The patient has to put his 2 hands and 2 foots on the machine. The machine do the measures during 2 minutes.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference of timing for Electrochemical skin conductance | the investigators will measure the timing between the 4 members for the Electrochemical skin conductance | 3 minutes |
Computer Program for Evaluation of the Symmetry Between the Primary Sulci of the Two Fetal Brain Hemispheres and Midsagittal Fetal Head Biometry Using 3-dimensional Ultrasound Planes.

Study Overview
=================
Brief Summary
-----------------
Computer Program for Evaluation of the Symmetry between the Primary Sulci of the Two Fetal Brain Hemispheres Using 3-dimensional Ultrasound Planes This retrospective study is based on the computerized analysis of the orthogonal fetal brain planes. The images are obtained from the digital archive of the fetal sonographic examinations done in Bnai Zion Medical Center. In addition, midsagittal measurements of fetal head will be obtained from this archive of 3-dimensional images. Study measurements will provide the quantitative parameters of normal fetal brain sulcation. Normal fetal head growth in midsagittal plane will be studied also.

Conditions
-----------------
Normal Fetal Brain Sulcation

Intervention / Treatment
-----------------
* Other: computerized analysis of sonographic images


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: normal pregnancies proper dating Exclusion Criteria: complications of pregnancy fetal malformations

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| normal pregnant<br> | Other: computerized analysis of sonographic images<br>* Evaluation of the Symmetry between the Primary Sulci of the Two Fetal Brain Hemispheres Using 3-dimensional Ultrasound Planes<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the safety profile of C2L-OCT-01 PR for up to an additional 96-week period in acromegalic patients who completed the C2L-OCT-01 PR-301 study.

Official Title
-----------------
Open Label Extension Study Evaluating the Safety and Biological Activity of a New Prolonged Release Formulation of Octreotide Acetate, C2L-OCT-01 PR, Administered Intra Muscularly Every 6, 5 or 4 Weeks in Acromegalic Patients

Conditions
-----------------
Acromegaly

Intervention / Treatment
-----------------
* Drug: C2L-OCT-01 PR 30 mg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: •Subjects who have completed the 24-week C2L-OCT-01 PR-301 study Exclusion Criteria: Women of childbearing potential who are not taking adequate contraception or who are pregnant or lactating Subjects who have experienced any clinically significant adverse event related to study medication in C2L-OCT-01 PR-301 study Subjects with uncontrolled Diabetes type II Subjects with signs or symptoms related to a tumor compression of the optical chiasm Subjects with symptomatic cholelithiasis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: C2L-OCT-01 PR 30 mg|Administered by deep IM (gluteus) on Day 1. Beginning on Day 42, drug injection frequency (6, 5 or 4 weeks) and dose modification/adjustment will be allowed for every 3 drug injections based on the mean serum GH and clinical symptoms obtained at the last visit of study C2L-OCT-01 PR-301 and during the course of this study.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess, for up to an additional 96 weeks, the safety profile of C2L-OCT-01 PR administered intra muscularly every 6, 5 or 4 weeks in patients who have completed the C2L-OCT-01 PR-301 study. |  | Up to 96 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine the percentage of patients who remain with controlled mean GH and normal (gender- and age-matched values) IGF-1 serum concentrations. |  | Up to 96 weeks | 
| Compare plasma concentrations of C2L-OCT-01 PR. |  | First 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acromegaly
Prenatal Molecular Characterisation by CGH+SNP-ARRAY of Supernumerary Marker Chromosomes and de Novo Apparently Balanced Reciprocal Translocations

Study Overview
=================
Brief Summary
-----------------
In the prenatal period, les supernumerary marker chromosomes (SMC) and de novo apparently balanced reciprocal translocations are revealed by foetal karyotyping, which does not always make it possible to determine whether the anomaly is balanced or not and does not reveal uniparental disomy. The presence of these chromosomal rearrangements raises a difficult question for genetic counselling during pregnancy because of the risk of intellectual deficiency in the foetus. CGH+SNP-Array can provide information concerning 1) the balanced or not nature of these translocations 2) the presence or not of euchromatin in the SMC 3) the presence or not of uniparental disomy.

Conditions
-----------------
Pre-natal Patient

Intervention / Treatment
-----------------
* Other: Blood samples


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Metaphase karyotyping with SMC or a de novo Apparently-balanced reciprocal translocation Parents covered by the National Health Insurance Agency, Consent of the parents Exclusion Criteria: Persons not covered by the National Health Insurance Agency Normal foetal karyotyping or showing chromosomal anomalies not related to the present study (trisomy 18….) or inherited anomalies Absence of a sample from one of the parents
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Pre-natal Patient<br> | Other: Blood samples<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| supernumerary chromosome markers |  | baseline |
INTUIT Hip Fracture Outcome Study

Study Overview
=================
Brief Summary
-----------------
The primary objective of this study is to characterize patients' course of recovery in the year following the initial surgery for unstable intertrochanteric hip fractures treated with the InterTAN intramedullary hip screw device. This will be done by collecting patient outcome measures of health related quality of life and functional status including return to normal gait. Secondary objectives are to document any adverse events associated with the procedure, and to analyze differences in recovery due to differences in age, gender, co-morbidities, nutrition, residence and ambulation status, and use of mobility aids.

Official Title
-----------------
Intramedullary Nailing for Treatment of Unstable InterTrochanteric (INTUIT) Hip Fracture Outcome Study.

Conditions
-----------------
Unstable Intertrochanteric Hip Fractures

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Unilateral unstable intertrochanteric hip fracture without other lower extremity fractures. Community and household ambulators with or without assistive devices. Age 50 years or greater. Exclusion Criteria: Stable intertrochanteric hip fracture. Bilateral or two or more lower extremity fractures. Non-functional ambulators or non-ambulators. Age less than 50 years.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mobility function as defined by the Timed Up & Go (TUG) frequency. |  | Baseline, Post-Operatively at 2 Weeks, 6 Weeks, 3 Months, 6 Months and 12 Months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lower Extremity Activity Scale |  | Baseline, Post-Operatively at 2 Weeks, 6 Weeks, 3 Months, 6 Months and 12 Months | 
| EuroQol |  | Baseline, Post-Operatively at 2 Weeks, 6 Weeks, 3 Months, 6 Months and 12 Months | 
| Visual Analogue Score (VAS) |  | Baseline, Post-Operatively at 2 Weeks, 6 Weeks, 3 Months, 6 Months and 12 Months | 
| Adverse Event |  | When necessary | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hip, Fracture, Intertrochanteric, intramedullary